Clients

Company          Services          Expertise          Clients          Publications          Contact          Blog hh

 

Selection of current and past services delivered to clients

  1. AufzählungszeichenStrategic consultancy

  2. -Epilepsy, mid-sized pharma company, EU, 2018

  3. -Multiple sclerosis, major pharma company, EU, 2016 – 2017

  4. -Paediatric epilepsy, mid-sized pharma company, EU, 2015 - 2016

  5. -In-licencing, neuroendocrine tumour, mid-sized pharma company, EU, 2014 - 2015

  6. -Biosimilar in multiple sclerosis, mid-sized pharma company, EU, 2010 – 2017

  7. -Cognitive disorder, CRO and start-up company, EU, 2014

  8. -Neurodegeneration in multiple sclerosis, major pharma company, MENA region, 2014

  9. -Liposomal drug delivery to the brain, start-up company, EU, 2014

  10. -Follow-on compound in multiple sclerosis, mid-sized pharma company, EU, 2012 – 2013

  11. -In-licencing, biosimilar in multiple sclerosis, mid-sized pharma company, EU, 2012 – 2013

  12. -Translational project in spinal-cord injury, bank, EU, 2011


  1. PuceInterim management at global level

  2. -Multiple sclerosis Phase IIIb and managed access, major pharma company, EFTA region, 2017 - 2018

  3. -Multiple sclerosis Phase III, major pharma company, EFTA region, 2015 - 2016

  4. -Multiple sclerosis Phase II, major pharma company, EFTA region, 2015

  5. -Fragile X syndrome Phase III, major pharma company, EFTA region, 2014 - 2015

  6. -Multiple sclerosis Phase II, major pharma company, EFTA region, 2009 – 2010


  1. PuceMember of scientific Advisory Boards

  2. -Multiple sclerosis, major pharma company, EU region, 2017 - 2018

  3. -Multiple sclerosis, major pharma company, EU, 2016

  4. -Acute neurological condition, start-up company, EU, 2014

  5. -Neuro-ophthalmology, major pharma company, EFTA region, 2012

  6. -Multiple sclerosis, mid-sized pharma company, EU, 2010 – 2012

  7. -Multiple sclerosis, major pharma company, EFTA region, 2010


  1. PuceMember of Study Steering Committees

  2. -Long-term follow-up study, major pharma company, EFTA region, 2014 – 2017

  3. -Global biosimilar study, mid-sized pharma company, EU, 2011 – 2015


  1. PuceMedical expertise in neurology, neuro-ophthalmology, immunology, and stroke

  2. -Major pharma company, EFTA region, 2015 - 2017

  3. -Mid-sized pharma company, EU, 2014 – 2015

  4. -Major pharma company, EFTA region, 2009 – 2014


  1. PuceScientific intelligence in neurological indications

  2. -Mid-sized pharma company, EU, 2012 – 2014

  3. -Mid-sized pharma company, EU, 2012 – 2013


  1. PuceCoaching and training of employees in drug development and multiple sclerosis

  2. -Major pharma company, EFTA region, 2018

  3. -Major pharma company, EFTA region, 2015 – 2016

  4. -Major pharma company, EFTA region, 2012 – 2014

  5. -Mid-sized pharma company, EU, 2013